Pregabalin effects on neural response to emotional faces

Pregabalin has shown promise in the treatment of anxiety disorders. Previous functional magnetic resonance imaging (fMRI) studies indicate agents used to treat anxiety, e.g., SSRIs and benzodiazepines, attenuate amygdala, insula, and medial prefrontal cortex (mPFC) activation during emotional processing. Our prior study has shown that during anticipation of an emotional stimulus, pregabalin attenuates amygdala and insula activation but increases medial PFC activation. In this study, we examined whether, similar to SSRIs and benzodiazepines, pregabalin attenuates amygdala, insula, and medial PFC during emotional face processing. Sixteen healthy volunteers underwent a double-blind within-subjects fMRI study investigating effects of placebo, 50 mg, and 200 mg pregabalin on neural activation during an emotional face-matching task. Linear mixed model analysis revealed that pregabalin dose-dependently attenuated left amygdala activation during fearful face-matching and left anterior insula activation during angry face-matching. The 50 mg dose exhibited more robust effects than the 200 mg dose in the right anterior insula and ventral ACC. Thus, pregabalin shares some similarity to SSRIs and benzodiazepines in attenuating anger and fear-related insula and amygdala activation during emotional face processing. However, there is evidence that a subclinical 50 mg dose of pregabalin produced more robust and widespread effects on neural responses in this paradigm than the more clinically relevant 200 mg dose. Taken together, pregabalin has a slightly different effect on brain activation as it relates to anticipation and emotional face processing, which may account for its unique characteristic as an agent for the treatment of anxiety disorders.

[1]  Greg J Siegle,et al.  Neurobiological correlates of cognitions in fear and anxiety: A cognitive–neurobiological information-processing model , 2012, Cognition & emotion.

[2]  P. Whalen,et al.  The structural and functional connectivity of the amygdala: From normal emotion to pathological anxiety , 2011, Behavioural Brain Research.

[3]  I. Liberzon,et al.  The Neurocircuitry of Fear, Stress, and Anxiety Disorders , 2011, Neuropsychopharmacology.

[4]  A. Simmons,et al.  Pregabalin Influences Insula and Amygdala Activation During Anticipation of Emotional Images , 2011, Neuropsychopharmacology.

[5]  M. Wessa,et al.  How to regulate emotion? Neural networks for reappraisal and distraction. , 2011, Cerebral cortex.

[6]  A. Craig.  Significance of the insula for the evolution of human awareness of feelings from the body. , 2011, Annals of the New York Academy of Sciences.

[7]  T. Egner,et al.  Emotional processing in anterior cingulate and medial prefrontal cortex , 2011, Trends in Cognitive Sciences.

[8]  A. Hariri,et al.  The amygdala: inside and out , 2011, F1000 biology reports.

[9]  D. Nutt,et al.  The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies , 2011, Journal of psychopharmacology.

[10]  M. Paulus,et al.  Neural systems underlying approach and avoidance in anxiety disorders , 2010, Dialogues in clinical neuroscience.

[11]  S. R. Staugaard.  Threatening faces and social anxiety: a literature review. , 2010, Clinical psychology review.

[12]  Murray B Stein,et al.  The pharmacologic treatment of anxiety disorders: a review of progress. , 2010, The Journal of clinical psychiatry.

[13]  Sara E. Morrison,et al.  Re-valuing the amygdala , 2010, Current Opinion in Neurobiology.

[14]  R. Lydiard,et al.  Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. , 2010, The international journal of neuropsychopharmacology.

[15]  Siegfried Kasper,et al.  Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study , 2010, NeuroImage.

[16]  D. Nutt,et al.  Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model , 2009, Journal of psychopharmacology.

[17]  P. McGuire,et al.  Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. , 2009, Journal of psychiatry & neuroscience : JPN.

[18]  A. Simmons,et al.  Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. , 2009, The international journal of neuropsychopharmacology.

[19]  J. Tanaka,et al.  The NimStim set of facial expressions: Judgments from untrained research participants , 2009, Psychiatry Research.

[20]  T. Einarson,et al.  Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. , 2009, Clinical therapeutics.

[21]  Thomas T. Liu,et al.  Caffeine reduces resting-state BOLD functional connectivity in the motor cortex , 2009, NeuroImage.

[22]  Raymond H. Phillippi,et al.  The Direct and Indirect Costs of Employee Depression, Anxiety, and Emotional Disorders—An Employer Case Study , 2009, Journal of occupational and environmental medicine.

[23]  Anna-Mari Aalto,et al.  General health and quality-of-life measures in active, recent, and comorbid mental disorders: a population-based health 2000 study. , 2009, Comprehensive psychiatry.

[24]  Valérie Ferreira,et al.  Current use of benzodiazepines in anxiety disorders , 2009, Current opinion in psychiatry.

[25]  Brian Knutson,et al.  Anticipatory affect: neural correlates and consequences for choice , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.

[26]  D. Baldwin.  Room for improvement in the pharmacological treatment of anxiety disorders. , 2008, Current pharmaceutical design.

[27]  G. Papadimitriou,et al.  Pregabalin in the discontinuation of long‐term benzodiazepines' use , 2008, Human psychopharmacology.

[28]  Ralph Adolphs,et al.  Fear, faces, and the human amygdala , 2008, Current Opinion in Neurobiology.

[29]  A. Simmons,et al.  Escitalopram effects on insula and amygdala BOLD activation during emotional processing , 2008, Psychopharmacology.

[30]  H. Wittchen,et al.  Human and economic burden of generalized anxiety disorder , 2008, Depression and anxiety.

[31]  M. Botvinick.  Conflict monitoring and decision making: Reconciling two perspectives on anterior cingulate function , 2007, Cognitive, affective & behavioral neuroscience.

[32]  A. Etkin,et al.  Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. , 2007, The American journal of psychiatry.

[33]  Rebecca Elliott,et al.  Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study , 2007, Neuroreport.

[34]  Richard Rogers,et al.  The anxiolytic effects of midazolam during anticipation to pain revealed using fMRI. , 2007, Magnetic resonance imaging.

[35]  M. Paulus,et al.  Role of Functional Magnetic Resonance Imaging in Drug Discovery , 2007, Neuropsychology Review.

[36]  Justin S. Feinstein,et al.  Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. , 2007, The American journal of psychiatry.

[37]  S. Donevan,et al.  Ca2+ channel α2δ ligands: novel modulators of neurotransmission , 2007 .

[38]  Justin S. Feinstein,et al.  Lorazepam dose-dependently decreases risk-taking related activation in limbic areas , 2006, Psychopharmacology.

[39]  M. Paulus,et al.  An Insular View of Anxiety , 2006, Biological Psychiatry.

[40]  N. Singewald,et al.  The role of substance P in stress and anxiety responses , 2006, Amino Acids.

[41]  S. Kasper,et al.  Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. , 2006, The Journal of clinical psychiatry.

[42]  Guy M. Goodwin,et al.  Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.

[43]  I. Hindmarch,et al.  A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers , 2005, Psychopharmacology.

[44]  Yoshiro Okubo,et al.  Effects of dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI study , 2005, NeuroImage.

[45]  Rebecca Elliott,et al.  The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study , 2005, Neuropsychopharmacology.

[46]  M. Pollack,et al.  Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. , 2005, Archives of general psychiatry.

[47]  Olga V. Demler,et al.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[48]  R. Elliott,et al.  Neuronal effects of acute citalopram detected by pharmacoMRI , 2005, Psychopharmacology.

[49]  J. Gross,et al.  The cognitive control of emotion , 2005, Trends in Cognitive Sciences.

[50]  R. Fieve,et al.  Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo-Controlled Comparison of BID versus TID Dosing , 2005, Journal of clinical psychopharmacology.

[51]  Justin S. Feinstein,et al.  Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. , 2005, Archives of general psychiatry.

[52]  S. Rauch,et al.  A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. , 2005, Archives of general psychiatry.

[53]  Anders Hay-Schmidt,et al.  Modulation of anxiety circuits by serotonergic systems , 2005, Stress.

[54]  J. Davidson,et al.  Efficacy of the Novel Anxiolytic Pregabalin in Social Anxiety Disorder: A Placebo-Controlled, Multicenter Study , 2004, Journal of clinical psychopharmacology.

[55]  H. Critchley,et al.  Neural systems supporting interoceptive awareness , 2004, Nature Neuroscience.

[56]  John A Detre,et al.  Precision of the CASL‐perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories , 2003, Journal of magnetic resonance imaging : JMRI.

[57]  J. Atack,et al.  Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. , 2003, Current drug targets. CNS and neurological disorders.

[58]  R. Shrivastava,et al.  A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients With Generalized Anxiety Disorder , 2003, Journal of clinical psychopharmacology.

[59]  M. Millan,et al.  The neurobiology and control of anxious states , 2003, Progress in Neurobiology.

[60]  R. Lydiard.  The role of GABA in anxiety disorders. , 2003, The Journal of clinical psychiatry.

[61]  J. Davidson,et al.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial. , 2003, The American journal of psychiatry.

[62]  M. Vaswani,et al.  Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[63]  Gregory G. Brown,et al.  Increased amygdala activation to angry and contemptuous faces in generalized social phobia. , 2002, Archives of general psychiatry.

[64]  Francesco Fera,et al.  The Amygdala Response to Emotional Stimuli: A Comparison of Faces and Scenes , 2002, NeuroImage.

[65]  H. Clusmann,et al.  Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex , 2002, Neuropharmacology.

[66]  J L Lancaster,et al.  Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.

[67]  R B Buxton,et al.  A theoretical and experimental comparison of continuous and pulsed arterial spin labeling techniques for quantitative perfusion imaging , 1998, Magnetic resonance in medicine.

[68]  R W Cox,et al.  AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. , 1996, Computers and biomedical research, an international journal.

[69]  T. Åkerstedt,et al.  Subjective and objective sleepiness in the active individual. , 1990, The International journal of neuroscience.

[70]  A. Craig,et al.  How do you feel — now? The anterior insula and human awareness , 2009, Nature Reviews Neuroscience.

[71]  R. Hen,et al.  The serotonergic system and anxiety , 2007, NeuroMolecular Medicine.

[72]  E. Boyce,et al.  Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. , 2007, Clinical therapeutics.

[73]  T. Feuerstein,et al.  Differential modulation of K+-evoked 3H-neurotransmitter release from human neocortex by gabapentin and pregabalin , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[74]  S. Donevan,et al.  Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. , 2007, Trends in pharmacological sciences.

[75]  E. Boyce,et al.  Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. , 2007, Clinical therapeutics.

[76]  S. Rauch,et al.  Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. , 2003, Psychopharmacology bulletin.

[77]  Michael Davis,et al.  The amygdala: vigilance and emotion , 2001, Molecular Psychiatry.

[78]  C. Spielberger,et al.  Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire" , 1983 .

[79]  C. Spielberger,et al.  Manual for the State-Trait Anxiety Inventory , 1970 .